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Abstract
Background: Cardiovascular diseases (CVDs) and cancers are the major causes of chronic arsenic exposure-related
morbidity and mortality. Matrix metalloproteinase-2 (MMP-2) and −9 (MMP-9) are deeply involved in the
pathogenesis of CVDs and cancers. This study has been designed to evaluate the interactions of arsenic exposure
with serum MMP-2 and MMP-9 concentrations especially in relation to the circulating biomarkers of CVDs.
Methods: A total of 373 human subjects, 265 from arsenic-endemic and 108 from non-endemic areas in Bangladesh
were recruited for this study. Arsenic concentrations in the specimens were measured by inductively coupled plasma
mass spectroscopy (ICP-MS) and serum MMPs were quantified by immunoassay kits.
Results: Serum MMP-2 and MMP-9 concentrations in arsenic-endemic population were significantly (p < 0.001) higher
than those in non-endemic population. Both MMPs showed significant positive interactions with drinking
water (rs = 0.208, p < 0.001 for MMP-2; rs = 0.163, p < 0.01 for MMP-9), hair (rs = 0.163, p< 0.01 for MMP-2; rs = 0.173, p < 0.01
for MMP-9) and nail (rs = 0.160, p< 0.01 for MMP-2; rs = 0.182, p < 0.001 for MMP-9) arsenic of the study subjects. MMP-2
concentrations were 1.02, 1.03 and 1.05 times, and MMP-9 concentrations were 1.03, 1.06 and 1.07 times
greater for 1 unit increase in log-transformed water, hair and nail arsenic concentrations, respectively, after
adjusting for covariates (age, sex, BMI, smoking habit and hypertension). Furthermore, both MMPs were increased
dose-dependently when the study subjects were split into three (≤10, 10.1-50 and > 50 μg/L) groups based on the
regulatory upper limit of water arsenic concentration set by WHO and Bangladesh Government. MMPs were also found
to be significantly (p < 0.05) associated with each other. Finally, the concentrations of both MMPs were correlated with
several circulating markers related to CVDs.
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Conclusions: This study showed the significant positive associations and dose–response relationships of
arsenic exposure with serum MMP-2 and MMP-9 concentrations. This study also showed the interactions of
MMP-2 and MMP-9 concentrations with the circulating markers of CVDs suggesting the MMP-2 and MMP-9 -mediated
mechanism of arsenic-induced CVDs.
Keywords: Arsenic, MMP-2, MMP-9, Cardiovascular diseases, Cancer, Bangladesh
Background
Arsenic is a potent environmental pollutant and a well
established human carcinogen. Chronic exposure to
arsenic is associated with a variety of diseases such as
cancers, dermatitis, CVDs, neurological disorders, dia-
betes mellitus, renal failure and liver dysfunction [1–9].
Exposure to arsenic through drinking water is a major
threat to the public health in many countries especially
in Bangladesh, India, Taiwan, China, Vietnam, Cambodia
and Mongolia. Arsenic poisoning has turned into tragedy
causing thousands of deaths in Bangladesh. About 80–100
million people are at risk of arsenic toxicity in the country
because of the consumption of higher concentrations of
arsenic through drinking water as compared to the per-
missive limit set by World Health Organization (WHO).
Recent reports suggest that arsenic has entered the food
chain including rice and vegetables [10, 11]. Presence of
excessive amount of arsenic in foods and vegetables
indicate that exposure to arsenic is unavoidable.
Matrix metalloproteinases (MMPs) are a family of
zinc-dependent proteolytic enzymes that degrade various
components of extracellular matrix (ECM). ECM and
their components are organized by a complex structure
of collagens, elastins, gelatins, laminins, fibronectins,
and proteoglycans. Rigorous regulation of MMP produc-
tion and activation is a crucial part of the homeostasis of
ECM. Impaired collagen and ECM homeostasis may be
among the underlying molecular mechanisms that lead
to the development of CVDs and cancers. Among the
MMPs, MMP-2 (gelatinase A) and MMP-9 (gelatinase B)
have been widely studied that degrade both gelatins and
collagens of ECM. MMP-2 and MMP-9 activities are
largely regulated by tissue inhibitor of metalloproteinase-1
(TIMP-1) [12, 13]. These MMPs have been implicated in
cardiovascular and cancer pathology through the degrad-
ation of ECM. In cardiovascular pathology, elevated MMP
activities have been reported to be linked to atheroscler-
otic plaque formation and plaque instability [14, 15]. In
cancer pathology, MMP-2 and MMP-9 are mainly impli-
cated in the formation of new blood vessels through
angiogenesis. MMP-2 and MMP-9 facilitate the migration
of tumor cells to blood vessels by the degradation of base-
ment membrane ECM proteins. CVDs and cancers are
the major causes of chronic arsenic exposure-related mor-
bidity and mortality, however, underlying mechanisms of
these arsenic-induced diseases remains to be clarified. Al-
though MMPs are deeply implicated in several chronic
diseases, previously only a limited number of human stud-
ies have evaluated the effect of chronic arsenic exposure
on MMPs [16–19]. Furthermore, the interaction of MMPs
with arsenic-induced chronic diseases especially CVDs
have not yet been documented clearly. Therefore, this
study has been designed to evaluate the interactions of ar-
senic exposure with serum MMP-2 and MMP-9 concen-
trations in humans especially in relation to the circulating
biomarkers of CVDs.
Methods
Study areas and study subjects
Ethical permission was taken from the Institute of
Biological Sciences, University of Rajshahi, Bangladesh
(21/320-IAMEBBC/IBSc). The human subjects who
participated in this study gave their written consent.
Confidentialities and rights of the study subjects were
strictly maintained. Arsenic-endemic and non-endemic
study areas for this study were selected as we described
previously [3, 9, 20–24]. Arsenic-endemic areas were se-
lected from the north-west region of Bangladesh that in-
cluded Marua in Jessore, Dutpatila, Jajri, Vultie and
Kestopur in Chuadanga, and Bheramara in Kushtia district
of Bangladesh. Chowkoli, a village in Naogaon district
with no history of arsenic contamination was selected as a
non-endemic area. Local residents (15–60 years of ages)
who had lived for at least five years in arsenic-endemic
and non-endemic areas were recruited for this study. The
study subjects were selected from the convened group,
irrespective of the presence or absence of arsenic-induced
skin symptoms (melanosis, leukomelanosis and keratosis).
Subsequently, individuals who did exhibit skin symptoms
were first identified by a physician and then the diagnosis
was confirmed by a dermatologist. The physician involved
in this study carefully examined various parts of the body
to confirm the presence of skin lesions.
During the sample collection process, we were blinded
to arsenic concentrations in the drinking water, and to
those in the hair and nails of the study participants.
Attempts were made to match, as much as possible age,
sex and socioeconomic parameters (occupation, monthly
income and education) in the two population groups se-
lected from arsenic-endemic and non-endemic areas.
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The ratio of male to female study subjects was ap-
proximately 1:1.
Pregnant and lactating mothers, and the individuals
who had previous and recent history of surgical oper-
ation, drug addiction, hepatitis B positive, hepatotoxic
and anti-hypertensive drugs, malaria, kalazar, chronic al-
coholism, previous and present history of hepatic, renal
or severe cardiac diseases have been excluded from this
study. Of the 274 individuals who were approached, 9
were excluded according to the exclusion criteria [i.e.,
study candidates (n = 4) who had reside in arsenic-
endemic areas for less than 5 years, pregnant and lactat-
ing mothers (n = 3), and had hepatic diseases (n = 2)];
thus a total of 265 individuals were finally recruited in
arsenic-endemic areas. In non-endemic area, four [i.e.,
study candidates (n = 1) who had resided in the non-
endemic area for less than 5 years, pregnant and lactat-
ing mothers (n = 2), study subjects who underwent re-
cent surgical operation (n = 1)] from a total of 112
individuals were excluded. The number of final partici-
pants was 108 in non-endemic area.
Household visits were carried out to interview resi-
dents. Personal interview of the study subjects was car-
ried out by the trained members of our research team
using a standard questionnaire. Information obtained
from the interview included the sources of water for
drinking and daily house hold uses, water consumption
history, socioeconomic status, occupation, food habit,
general food items consumed daily, cigarette smoking,
alcohol intake, personal medical history, history of
diseases, physiological complications, major diseases,
previous physician’s reports, and BMI. We collected all
blood and other specimens (including water samples) on
the same day at each site.
Blood pressure measurement
The standard protocol for measuring blood pressure rec-
ommended by WHO, was used in this study. After study
subjects had rested for 20 min or longer, both systolic
and diastolic blood pressures (SBP and DBP) were mea-
sured three times with a mercury sphygmomanometer
with subjects sitting. SBP and DBP were defined at the
first and fifth phase Korotkoff sounds, respectively. The
average of three measurements was used for the analysis.
Hypertension was defined as a SBP of ≥ 140 mm Hg and
a DBP of ≥ 90 mm Hg on three repeated measurements.
Collection of serum and examination for Hepatitis B
All study subjects were requested to fast overnight (10–
12 h), and fasting blood samples (5–7 ml) were collected
from each individual by venipuncture into blood collection
tubes. The blood samples were left at room temperature
for 30 min for clotting, and were subsequently centrifuged
at 1200 × g for 20 min. The serum supernatant was then
taken and stored at -80 °C. All serum samples were
checked for hepatitis B using a 3rd-generation HBsAg
ELISA test kit (Medivent Diagnostic & Co. Ltd., Ireland)
according to the manufacturer’s protocol.
Water collection and arsenic analysis
Tube well water identified by study subjects as primary
sources of their drinking water were collected for this
study as described by Ali et al. [23]. Water samples from
tube wells were collected in acid-washed containers after
the well was pumped for 5 min as described previously
[25]. Total arsenic concentrations in water samples were
determined by inductively coupled plasma mass spec-
troscopy (ICP-MS), (HP-4500, Agilent Technologies,
Kanagawa, Japan) after the addition of a solution of yt-
trium (10 ppb in 1.0 % nitric acid) to all water samples
as an internal standard for ICP-MS analysis. All samples
were determined in triplicate and the average values
were used for data analysis. Accuracy of water arsenic
measurement was verified using a certified reference ma-
terial (CRM). “River water” (NMIJ CRM 7202-a No.347
National Institute of Advanced Industrial Science and
Technology, Japan) was used as a CRM. The average
value (mean ± SD) of arsenic in the “river water” deter-
mined in triplicate by ICP-MS analysis was 1.06 ± 0.04 μg/L
(reference value, 1.18 μg/L).
Collection of hair and nail samples, and analysis of arsenic
Arsenic concentrations in finger nails and hair have been
reported to provide the integrated measures for arsenic
exposure [26, 27]. Hair and nails of the study subjects
were collected and washed by the method as described
previously [23]. The washed samples were allowed to
dry at 60 °C overnight and digested with concentrated
nitric acid using a hot plate at 70 °C for 15 min and
115 °C for 15 min. After cooling, the samples were di-
luted with 1.0 % nitric acid containing yttrium (10 ppb).
The concentrations of arsenic and yttrium in these sam-
ples were determined by ICP-MS. All samples were de-
termined in triplicate and the average values were used.
Accuracy of arsenic measurement was verified using
“human hair” (GBW09101, Shanghai Institute of Nuclear
Research Academia Sinica, China) as a CRM. The
average value (mean ± SD) of arsenic in “human hair” deter-
mined in triplicate by ICP-MS analysis was 0.61 ± 0.12 μg/g
(reference value, 0.59 μg/g).
Measurements of serum MMP-2 and MMP-9
Serum concentrations of MMP-2 and MMP-9 were
measured using commercially available enzyme-linked
immunoassay kits (MMP-2 from R&D Systems, Inc.
Minneapolis, USA, and MMP-9 from Invitrogen Corpor-
ation, Camarillo, CA) according to the manufacture’s
protocols. A micro-plate reader (Mikura Ltd. UK) was
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used for the measurement of color development. All
standards and samples were analyzed in duplicate. The
intra and inter assay coefficients of variations (CVs) were
maximum 10 %.
Statistical analysis
Descriptive statistics were calculated to compare the
study subjects of non-endemic and arsenic-endemic
areas by independent sample t-test for continuous
variables, and chi-square test for categorical variables.
Variables (MMP-2, MMP-9, water, hair and nail arsenic)
were log-transformed to improve the approximation to
the normal distribution. Normality of the variables dis-
tribution was verified by a Q-Q plot. Comparisons of
MMP-2 and MMP-9 concentrations between the two
population groups in arsenic-endemic and non-endemic
areas were analyzed by independent sample t-test. Spear-
man correlation coefficient tests were used to evaluate
the correlations of MMP-2 and MMP-9 concentrations
with arsenic exposure metrics (water, hair and nail ar-
senic). The nature of any association between arsenic ex-
posure metrics and MMPs was evaluated by scatter plot
analysis. Study subjects in the arsenic-endemic areas
were split into two (medium and high) groups based on
the two concentrations (water, hair and nail) of each ex-
posure metric with equal proportion through frequency
test, and study subjects in the non-endemic area were
used as a reference group (low exposure group). MMP-2
and MMP-9 concentrations for the low, medium and
high arsenic exposure metrics were analyzed by general
linear model univariate regression followed by Bonferroni
multiple comparison tests. We estimated the ratios of the
geometric means of MMP-2 and MMP-9 which were
interpreted as exponentiated regression coefficients. The
linear model univariate regression analyses were per-
formed before (Model 1) and after (Model 2) adjusting
for relevant covariates (age, sex, BMI, smoking and hyper-
tension). Study subjects were further split into three
(≤10 μg/L, 10.1-50 μg/L and > 50 μg/L) groups based on
the regulatory upper limit for water arsenic concentrations
set by WHO (10 μg/L) and Bangladesh Government
(50 μg/L). MMP-2 and MMP-9 concentrations in the
three groups were evaluated by one way ANOVA test
(Bonferroni). Spearman correlation coefficient test was
used to evaluate the correlation between serum MMP-2
and MMP-9 concentrations. Correlations of MMP-2
and MMP-9 with high density lipoprotein cholesterol
(HDL-C), intercellular adhesion molecule-1 (ICAM-1)
and vascular cell adhesion molecule-1 (VCAM-1) were
evaluated by Spearman correlation coefficient test.
Statistical analysis for this study was done with Statistical
Package for the Social Sciences (SPSS version 17.0,
SPSS Inc., Chicago, IL). A value of p < 0.05 was con-
sidered statistically significant.
Results
Table 1 shows some general characteristics of the study
populations in arsenic-endemic (n = 265) and non-
endemic areas (n = 108). There were 145 male and 120
female study subjects in arsenic-endemic areas, and
these were 53 and 55, respectively, in non-endemic area.
Since attempts were made to match, as much as possible
age, sex and socioeconomic parameters (occupation,
education and monthly income) between the two popu-
lation groups in arsenic-endemic and non-endemic
areas, no significant differences were observed in those
parameters between the two study populations. The
average ages (mean ± SD) of the arsenic-endemic and
non-endemic study populations were 38.32 ± 11.79 years
and 35.84 ± 11.17 years, respectively. A good number of
male and female study subjects were farmers and house-
wives, respectively, in both arsenic-endemic and non-
endemic areas. More than 50 % of the study subjects in
arsenic endemic and non-endemic areas had no formal
education. The average (mean ± SD) monthly incomes
of the study subjects in both arsenic-endemic and
non-endemic areas were almost similar. The average
(mean ± SD) levels of systolic blood pressure (SBP) and
diastolic blood pressure (DBP) of the study population in
arsenic-endemic areas were significantly (p < 0.001) higher
than those in non-endemic area. Accordingly numbers of
hypertensive study subjects were also higher in arsenic-
endemic areas than those in non-endemic area. A large
number (69.43 %) of study subjects in arsenic-endemic
areas had typical skin symptoms of arsenicosis. No female
was found to be a smoker since generally women in
Bangladesh do not smoke cigarette. None of the study
subjects admitted to drinking alcohol. Bangladeshi people
generally do not drink alcohol because of religious and so-
cial restrictions on alcohol drinking. The average levels of
BMI (mean ± SD) were almost similar between the two
population groups. The range of drinking water arsenic
concentrations in the study populations in arsenic-
endemic and non-endemic areas were 0.11–546 μg/L and
0.03–13.17 μg/L, respectively. The 25th, 50th, 75th, 90th
percentile values of water arsenic in arsenic-endemic indi-
viduals were 36.1, 133.8, 263, and 400 μg/L, respectively,
where as these were 0.04, 1.18, 2.98 and 5.32 μg/L, re-
spectively, in non-endemic individuals. Arsenic concentra-
tions in the drinking water, hair and nails of the study
subjects in arsenic-endemic areas were approximately
136, 12 and 8 times higher, respectively than those in
non-endemic area.
Table 2 shows the comparison of MMP-2 and MMP-9
concentrations between the study populations in
arsenic-endemic and non-endemic areas. The average
(Geometric mean ±GSD) value of MMP-2 and MMP-9
concentrations in the population group in arsenic-endemic
areas were 225.20 ± 1.40 ng/mL and 54.43 ± 1.73 ng/mL,
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respectively, while these were 191.90 ± 1.50 ng/mL
and 41.14 ± 1.56 ng/mL respectively, in the population
group in non-endemic area. Both MMPs were found
to be significantly (p < 0.001 for both MMPs) higher
in arsenic-endemic population than in non-endemic
population.
Table 3 shows the correlations of arsenic exposure
metrics (water, hair and nail arsenic concentrations) with
Table 1 Descriptive characteristic of the study populations in arsenic-endemic and non-endemic areas
Parameters Non-endemic Arsenic-endemic p-value
Total subjects (n) 108 265
Sex (n) Male 53 145
Female 55 120
Age (years)a 35.84 ± 11.17 38.32 ± 11.79 0.062*
Occupation [n, (%)] Male 0.259†
Farmers 37 (69.81) 126 (86.90)
Business 0 6 (4.14)
Students 13 (24.53) 4 (2.76)
Tailors 0 2 (1.38)
+Others 3 (5.66) 7 (4.83)
Female
Housewives 53 (96.36) 114 (95.00)
Farm workers 2 (3.64) 2 (1.67)
Students 0 3 (2.50)
‡Others 0 1 (0.83)
Education [n, (%)] No formal education 62 (57.41) 143 (53.96) 0.397†
Primary 39 (36.11) 93 (35.09)
Secondary 5(4.63) 26 (9.81)
Higher 1 (1.85) 3 (1.32)
Income/month (US$)a 22.95 ± 5.54 24.33 ± 8.86 0.071*
Systolic blood pressure (mmHg)a 110.1 ± 14.5 118.26 ± 15.21 <0.001*
Diastolic blood pressure (mmHg)a 69.81 ± 9.57 76.70 ± 9.60 <0.001*
Hypertension [n, (%)] Yes 2 (1.85) 35 (13.20) <0.01†
No 106 (98.15) 230 (86.80)
Skin symptom [n, (%)] (+) symptom 0 184 (69.43) <0.001†
(−) symptom 108 (100) 81 (30.57)
Smoking in male [n, (%)] Yes 20 (37.74) 59 (40.69) 0.707†
No 33(62.26) 86 (59.31)
Alcohol intake - - -
BMI (kg/m2)a 21.13 ± 2.78 20.53 ± 3.15 0.090*
Distribution of drinking water As (μg/L) Range (min-max) 0.03–13.17 0.11–546
25th percentile 0.04 36.1
50th percentile 1.18 133.8
75th percentile 2.98 263
90th percentile 5.32 400
Drinking water As (μg/L)b 0.56 ± 7.77 76.10 ± 5.91 <0.001*
Hair As (μg/g)b 0.23 ± 2.36 2.85 ± 2.97 <0.001*
Nail As (μg/g)b 0.80 ± 2.64 6.60 ± 2.49 <0.001*
Abbreviations: As arsenic. BMI was calculated as body weight (Kg) divided by height squared (m2). aMean ± SD. bGeometric Mean (GSD). *Independent sample
t-test and †chi-square test were used to test for sample differences in continuous and categorical variables, respectively. +Others included village doctor, security
guard, banker and worker. ‡Others included farmer
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serum MMP-2 and MMP-9 concentrations. Serum con-
centrations of MMP-2 and MMP-9 showed significant
positive correlations with arsenic in water (rs = 0.208,
p < 0.001 for MMP-2; rs = 0.163, p < 0.01 for MMP-9),
hair (rs = 0.163, p < 0.01 for MMP-2; rs = 0.173, p < 0.01
for MMP-9) and nails (rs = 0.160, p < 0.01 for MMP-2;
rs = 0.182, p < 0.001 for MMP-9). Dose–response rela-
tionships were tested into three arsenic exposure groups
of the study subjects: low (non-endemic), medium and
high (Table 4). Intriguingly, both MMP-2 and MMP-9
concentrations were found to be increased in the higher
exposure gradients of water, hair and nail arsenic concen-
trations. MMP-2 and MMP-9 concentrations were 1.02
and 1.03 times greater, respectively, for every 1-unit in-
crease in log-transformed water arsenic (μg/L), and were
1.03 and 1.06 times greater, respectively, for 1-unit in-
crease in log-transformed hair arsenic concentration
(μg/g) after adjusting for age, sex, BMI, smoking and
hypertension. For 1-unit increase in log-transformed
nail arsenic concentration (μg/g), MMP-2 and MMP-9
concentrations were 1.05 and 1.07 times greater, respect-
ively. Further study populations were divided into three
(≤10 μg/L, 10.1-50 μg/L and > 50 μg/L) groups based on
the regulatory upper limit of water arsenic concentrations
set by WHO (10 μg/L) and Bangladesh Government
(50 μg/L), and then serum MMP-2 and MMP-9 concen-
trations were compared in these three groups (Table 5).
Both MMPs were found to be gradually increased in
the higher gradients compared to the lower gradients
of water arsenic concentrations, however, significant
(p < 0.01 and p < 0.001 for MMP-2 and MMP-9, re-
spectively) differences were only observed in > 50 μg/L
versus ≤ 10 μg/L groups.
Since serum MMP-2 and MMP-9 concentrations
showed positive associations and dose–response rela-
tionships with arsenic exposure, we next investigated the
interrelationship of these two MMPs. Intriguingly, we
found that MMP-2 and MMP-9 concentrations were sig-
nificantly (p < 0.05) correlated with each other (Fig. 1).
We have previously investigated the associations of ar-
senic exposure with several circulating markers of CVDs
such as high density lipoprotein cholesterol (HDL-C),
intercellular adhesion molecule-1 (ICAM-1) and vascu-
lar cell adhesion molecule-1 (VCAM-1) on the same
population group selected for this study [3]. Positive as-
sociations of MMP-2 and MMP-9 concentrations with
arsenic exposure led us to analyze the relationship of
both MMPs with cardiovascular markers among the
study subjects who were common for the both previous
and present studies (Table 6). A good number of study
subjects in this study (n = 303 for HDL-C; n = 313 for
ICAM-1; n = 314 for VCAM-1) were overlapped with
our previous study [3]. MMP-9 but not MMP-2 showed
the significant (p < 0.01) inverse relationship with plasma
concentrations of HDL-C of the overlapping study sub-
jects of the two studies. Furthermore, significant positive
associations were observed between MMP-2 and VCAM-
1 (p < 0.05), between MMP-9 and VCAM-1 (p < 0.05), and
between MMP-9 and ICAM-1 (p < 0.01) concentrations.
Discussion
In this cross sectional study, serum MMP-2 and MMP-9
concentrations were found to be significantly higher in
arsenic-endemic population than those in non-endemic
population in rural Bangladesh (Table 2). Arsenic expos-
ure measured by drinking water (external exposure
metric), hair and nail (internal exposure metrics) showed
positive interactions and dose response relationship with
serum MMP-2 and MMP-9 concentrations (Tables 3, 4
and 5). Both MMPs were also significantly correlated
with each other (Fig. 1). Finally, elevated concentrations
of serum MMP-9, and to a lesser extent MMP-2, were
found to be linked to the several circulating biomarkers
(HDL-C, ICAM-1 and VCAM-1) associated with the
risk of CVDs (Table 6).
MMPs act as inflammatory mediators [28]. The major
cellular sources of MMPs are macrophages and neutrophils.
Table 2 Comparisons of Serum MMP-2 and MMP-9 concentrations
between the study populations in arsenic-endemic and
non-endemic areas
Parameters Non-endemic Arsenic-endemic p-value
Serum MMP-2 (ng/mL)a 191.90 (1.50) 225.20 (1.40) <0.001
(n = 108) (n = 261)
Serum MMP-9 (ng/mL)a 41.14 (1.56) 54.43 (1.73) <0.001
(n = 108) (n = 265)
aGeometric Mean (GSD). Log-transformed dependent variables were used.
p-values were from the Independent sample t-test
Table 3 Correlations of arsenic exposure with serum MMP-2 and MMP-9 concentrations
Exposure metrics MMP-2 (n = 369) MMP-9 (n = 373)
Correlation coefficient (rs) p-value Correlation coefficient (rs) p-value
Water arsenic 0.208 <0.001 0.163 <0.01
Hair arsenic 0.163 <0.01 0.173 <0.01
Nail arsenic 0.160 <0.01 0.182 <0.001
Log-transformed values were used. p-values were from Spearman correlation coefficient test
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Table 4 Associations of arsenic exposure with serum concentrations of MMP-2 and MMP-9
Water Arsenic (μg/L)
Low ( 0.03–13.17) Medium (0.11–133.8) High (134.12–546) Per log-transformed water As (μg/L)
(n = 108) (n = 133) (n = 132)
Exp (B) (95 % CI) Exp (B) (95 % CI) Exp (B) (95 % CI) Exp (B) (95 % CI)
GM (GSD)a 0.56 (7.78) 21.33 (5.47) 274.51 (1.51) -
MMP-2
Model 1 1.00 Reference group 1.14 (1.04–1.25) 1.20 (1.10–1.32) 1.02 (1.01–1.04)
Model 2 1.00 Reference group 1.12 (1.03–1.23) 1.20 (1.09–1.31) 1.02 (1.01–1.04)
GM (SE)d 191.90 (1.03) 219.64 (1.03)f** 230.67 (1.03)f***
Adj GM (SE)d 201.74 (1.05) 227.01 (1.04)f* 241.53 (1.04)f**
MMP-9
Model 1 1.00 Reference group 1.32 (1.15–1.50) 1.33 (1.17–1.52) 1.03 (1.01–1.05)
Model 2 1.00 Reference group 1.28 (1.12–1.46) 1.26 (1.13–1.48) 1.03 (1.01–1.05)
GM (SE)e 41.14 (1.05) 54.22 (1.05)f*** 54.65 (1.05)f**
Adj GM (SE)e 45.60 (1.07) 58.32 (1.06)f** 59.15 (1.06)f**
Hair Arsenic (μg/g)
Low (0.02–1.62) Medium (0.01–2.84) High (2.86–37.24) Per log-transformed hair As (μg/g)
(n = 108) (n = 133) (n = 132)
Exp (B) (95 % CI) Exp (B) (95 % CI) Exp (B) (95 % CI) Exp (B) (95 % CI)
GM (GSD)b 0.23 (2.36) 1.28 (2.28) 6.4 (1.91) -
MMP-2
Model 1 1.00 Reference group 1.14 (1.04–1.25) 1.21 (1.10–1.32) 1.03 (1.009–1.06)
Model 2 1.00 Reference group 1.13 (1.03–1.24) 1.20 (1.09–1.31) 1.03 (1.006–1.055)
GM (SE)d 191.90 (1.03) 219.2 (1.03)f* 231.6 (1.03)f***
Adj GM (SE)d 201.34 (1.05) 227.24 (1.04)f* 241.05 (1.04)f**
MMP-9
Model 1 1.00 Reference group 1.29 (1.13–1.47) 1.36 (1.19–1.55) 1.07 (1.03–1.11)
Model 2 1.00 Reference group 1.26 (1.10–1.44) 1.32 (1.15–1.51) 1.06 (1.03–1.10)
GM (SE)e 41.14 (1.05) 53.04 (1.05) f** 55.87 (1.05) f***
Adj GM (SE)e 45.60 (1.07) 57.40 (1.06)f** 60.16 (1.06) f**
Nail Arsenic (μg/g)
Low (0.03–8.13) Medium (0.22–6.79) High (6.91–47.83) Per log-transformed nail As (μg/g)
(n = 108) (n = 133) (n = 132)
Exp (B) (95 % CI) Exp (B) (95 % CI) Exp (B) (95 % CI) Exp (B) (95 % CI)
GM (GSD)c 0.80 (2.64) 3.21 (1.93) 13.65 (1.54) -
MMP-2
Model 1 1.00 Reference group 1.14 (1.04–1.25) 1.20 (1.10–1.32) 1.06 (1.03–1.09)
Model 2 1.00 Reference group 1.13 (1.03–1.23) 1.20 (1.09–1.32) 1.05 (1.03–1.08)
GM (SE)d 191.90 (1.03) 219.2 (1.03) f* 231.60 (1.03) f***
Adj GM (SE)d 200.34 (1.05) 225.65 (1.04)f* 240.33 (1.04) f**
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MMPs degrade ECM to facilitate migration and recruit-
ment of cells including inflammatory cells, and cleave cell
surface receptors and non-ECM molecules to mediate ad-
hesion, proliferation and apoptosis of cells in vessel wall
which are involved in the inflammatory process [29, 30].
Growing evidence suggests that MMP-2 and MMP-9 are
deeply implicated in CVDs and cancers through vascular
remodeling and the formation of new blood vessels (angio-
genesis and arteriogenesis) [31–34]. In matured and quies-
cent vessels, small amount of MMP-2 and MMP-9 are
expressed. But when tissue undergoes vascular remodeling
and abnormal angiogenesis in pathological conditions espe-
cially in CVDs and cancer, MMPs are markedly expressed,
secreted and activated. Atherosclerosis is the fundamental
event for CVDs. Formation of atherosclerotic plaque, and
its progression and rapture are largely mediated through in-
flammatory process [35]. MMPs take part in the early stage
of atherosclerotic process by enhancing migration and pro-
liferation of smooth muscle cells as well as other inflamma-
tory cells, whereas in advanced stage of atherosclerosis,
inflammation derived proteolytic activity of MMPs may
weaken and rapture the plaque [14]. Wågsäter et al. [36] in-
vestigated several MMPs, other proteases and TIMP-1, and
found that only MMP-2 and MMP-9 were involved in
atherogenesis in Ldlr−/−Apob100/100 mouse model which
had a plasma lipoprotein profile similar to that of humans
with atherosclerosis. In this mouse model, atherosclerotic
lesion development was found to be initiated by infiltrated
macrophage that mainly produced MMP-2 and MMP-9.
There have been discrepancies in the association of ar-
senic exposure with MMP-2 and MMP-9 concentrations
from one study to another. The results of this study are
in good agreement with the results reported by Burgess
et al. [16]. They found a positive correlation of MMP-9
concentrations with water arsenic concentrations of the
total population that include Mexicans, US Hispanic and
US Non-Hispanic individuals. A cross sectional study in
two communities in Arizona reported an effect of low
concentration of arsenic exposure on MMP-2, MMP-9
and their inhibitor TIMP-1 [17]. This study did not find
any significant differences in sputum MMP-2, MMP-9
and TIMP-1 concentrations in the relatively high exposed
population as compared to the low exposed population.
However, this study showed the negative associations
of total urinary arsenic with MMP-2 and TIMP-1,
and positive associations with the ratios of sputum
MMP-2/TIMP-1 and MMP-9/TIMP-1. Findings of our
study were different as compared with the study con-
ducted on the population in arsenic-endemic area in
Bangladesh by Wu et al. [18]. Wu’s study did not find any
significant positive association between arsenic exposure
and plasma MMP-9 concentrations. There were several
important differences in the characteristics of the study
populations between our study and Wu’s study. Arsenic
concentrations in the drinking water of our study subjects
were much higher than those of the study subjects se-
lected for Wu’s study. In our study, 14.48 % of individuals
were exposed to tube well water arsenic at concentrations
greater than 300 μg/L (data not shown), whereas 98 % of
the study subjects of Wu’s study were exposed to water
arsenic at concentrations less than 300 μg/L. Further
49.33 % of our study subjects had arsenic-induced typical
skin lesions (melanosis, leukomelanosis and keratosis),
whereas only 3.4 % of individuals of Wu’s study had skin
symptoms. Therefore, exposure to high concentrations of
arsenic and prevailing typical skin symptoms in a good
Table 4 Associations of arsenic exposure with serum concentrations of MMP-2 and MMP-9 (Continued)
MMP-9
Model 1 1.00 Reference group 1.30 (1.14–1.48) 1.35 (1.18–1.54) 1.08 (1.04– 1.12)
Model 2 1.00 Reference group 1.28 (1.12–1.47) 1.29 (1.13–1.48) 1.07 (1.02–1.11)
GM (SE)e 41.14 (1.05) 53.04 (1.05)f** 55.87 (1.05)f**
Adj GM (SE)e 45.56 (1.07) 58.38 (1.06)f** 58.97 (1.06) f**
n = number of study subjects. Study subjects in the non-endemic area were used as low exposure group or reference group. Model 2 adjusted for age, sex, BMI,
smoking and hypertension. Log transformed dependent and independent variables were used. aCategory specific geometric mean (GSD) values of water arsenic.
bCategory specific geometric mean (GSD) values of hair arsenic. cCategory specific geometric mean (GSD) values of nail arsenic. dCategory specific geometric mean
(SE) values of MMP-2. eCategory specific geometric mean (SE) values of MMP-9. fSignificantly different from low group. ***, p < 0.001; **, p < 0.01; *, p < 0.05
Table 5 MMP-2 and MMP-9 concentrations in three groups based on the regulatory limit of water arsenic
Parameters ≤10 μg/L 10.1–50 μg/L >50 μg/L p-value (F-test)
Serum MMP-2 (ng/mL)a 197.75 (1.48) 220.08 (1.37) 228.38 (1.40)** <0.01
(n = 144) (n = 44) (n = 181)
Serum MMP-9 (ng/mL)a 43.60 (1.59) 53.57 (1.75) 55.20 (1.75)*** <0.001
(n = 145) (n = 44) (n = 184)
n = number of study subjects. aGeometric Mean (GSD). **Significantly different from ≤ 10 μg/L group at p < 0.01. ***Significantly different from ≤ 10 μg/L group at
p < 0.001. p-values were from one way ANOVA test
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number of study subjects are the major characteristic fea-
tures of our study population that might make differences
in the results of our study from Wu’s study.
Our study showed not only associations but also
dose–response relationships of arsenic exposure with
serum MMP-2 and MMP-9 concentrations. MMP-2
concentrations were 1.02, 1.03 and 1.05 times, and
MMP-9 concentrations were 1.03, 1.06 and 1.07 times
greater for 1 unit increase in log-transformed water, hair
and nail arsenic concentrations, respectively (Table 4). In
addition, both MMPs were found to be increased dose-
dependently when the study subjects were split into
three groups based on the regulatory upper limit of water
arsenic concentration set by WHO and Bangladesh
Government (Table 5). In this study, hair and nail arsenic
concentrations corresponded well to the drinking water
arsenic concentrations of the study subjects (data not
shown) as we reported previously [23, 24]. These strong
interrelationships among exposure metrics could reduce
the bias in the observed associations of arsenic exposure
with MMPs. Wide variation of exposure concentrations,
good number of study population, consistent associations
of MMP-2 and MMP-9 concentrations across the three
kinds of exposure metrics (drinking water, hair and nail
arsenic), and the significant interrelationship between the
two MMPs are the main strengths of this study. Previous
studies used drinking water and urinary arsenic concen-
trations as exposure metrics to demonstrate the associa-
tions of arsenic exposure with MMPs [17, 18]. Urinary
arsenic does not reflect the historical or chronic exposure.
Arsenic concentrations in biologic tissues other than nails
and hair, such as blood or urine reflect recent exposure.
Arsenic is removed from the blood within a few hours
and excreted through the kidneys and urine within a few
days [37, 38]. Nail arsenic has been suggested to be an in-
dicator of historical or chronic exposure [39]. Hair arsenic
concentrations also represent historical exposure but
compared to nail, it represents relatively immediate
exposure. One centimeter of hair from the stem reflects
approximately one month of exposure. Therefore, assess-
ment of the effects of chronic arsenic exposure measured
by hair and nail arsenic on serum MMP-2 and MMP-9
concentrations was an additional strength of this study.
We selected the study subjects for this study who had
also attended the previous studies in which association of
arsenic exposure with circulating markers of CVDs were
investigated [3]. Therefore, positive associations of arsenic
exposure with serum MMP-2 and MMP-9 concentrations
on the same population group argued their implications in
the arsenic-induced cardiovascular pathogenesis. This ar-
gument was further supported by the observed associa-
tions of MMP-2 and MMP-9 concentrations with some
biomarkers related to CVDs (Table 6). MMP-9 showed
significant (p < 0.01) negative association with HDL-C.
Decreased serum HDL-C concentration is a traditional
biomarker of the risk of atherosclerosis leading to CVDs.
Significant negative relationship of serum MMP-9 with
HDL-C indicated the implication of serum MMP-9 con-
centrations in the development of atherosclerosis in
arsenic-affected people. Accumulating evidence suggests
that systemic inflammation and endothelial dysfunction
are two hallmark events of the development of CVDs
[40, 41]. Previously, on the same populations, we found
that arsenic exposure increased endothelial dysfunction that
was determined by plasma big-endothelin-1 (Big ET-1)
concentrations [22]. Activated endothelial cells express ad-
hesion molecules that mediate the attachment of circulating
leukocytes to the endothelium and their transmigration into
the arterial wall in the early step of atherosclerosis. Circulat-
ing adhesion molecules including ICAM-1 and VCAM-1
have been reported to be markers of future risk of CVDs
[42, 43]. Previously, we and others have also showed that
arsenic exposure increased the circulating ICAM-1 and
VCAM-1 [3, 18, 44]. More than 300 individuals of this
Fig. 1 Correlation between serum MMP-2 and MMP-9 concentrations.
p-value was from Spearman correlation coefficient test
Table 6 Correlations of MMP-2 and MMP-9 with HDL-C, ICAM-1
and VCAM-1
HDL-C ICAM-1 VCAM-1
MMP-2 rs −0.071 0.103 0.133
p-value 0.211 0.068 0.019
n 303 313 314
MMP-9 rs −0.178 0.157 0.130
p-value 0.002 0.005 0.021
n 303 313 314
n = number of study subjects overlapped with previous study [3]. p-values
were from Spearman correlation coefficient test
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study were overlapped with our previous study in terms of
ICAM-1 and VCAM-1. Intriguingly, we found significant
positive associations between MMP-2 and VCAM-1, be-
tween MMP-9 and ICAM-1, and between MMP-9 and
VCAM-1. Therefore, elevated concentrations of MMP-2
and MMP-9 observed in this study strongly argued
the involvement of these proteases in the pathophysiology
of arsenic-induced CVDs.
Although this study represents extensive epidemio-
logical research efforts to determine the effects of arsenic
exposure on serum MMP-2 and MMP-9 concentrations,
there were some potential limitations warranting further
discussion. One of the limitations of this study was to as-
sess only the serum MMP-2 and MMP-9 concentrations
but not their activities. MMP expression and activity do
not always correlate each other. Enzymatic activities of
MMPs are directly relevant to the biological functions.
Activities of serum TIMPs have also putative effects on
MMP activity. Previously Josyula et al. [17] have showed
an inverse relation between urinary inorganic arsenic and
sputum TIMP-1. Several in vitro studies have also demon-
strated that arsenic exposure increased the activities of
MMP-2 and MMP-9 [45–47]. Therefore, it is assumed
that increased concentrations of MMP-2 and MMP-9 with
the increasing concentration of arsenic observed in this
study may correspond to the activities of both MMPs. To
assess the effects of other variables in the observed associ-
ations of arsenic exposure with serum MMPs, adjustments
were made for covariates (age, sex, BMI, smoking habit
and hypertension), and the results explicitly demonstrated
that arsenic exposure was the main contributor to the in-
creasing concentrations of MMP-2 and MMP-9 in serum
(Table 4). However, there might be some other variables
or co-exposure of other metals that could influence the
observed associations. If co-exposure of other metals in-
fluenced the observed associations, they would follow the
same concentration gradients as arsenic did. It is unlikely;
however, probabilities could not be excluded completely.
Future study is needed in this regard. The study design
used here was a cross-sectional. A cohort based study is
needed in future to establish the cause-effect relationship
between arsenic exposure and serum MMPs. Most of our
study subjects in both arsenic endemic and non-endemic
areas were lean with regard to BMI. Furthermore, about
half of the study subjects had typical symptoms of arseni-
cosis. These characteristics of the study population may
limit the generalizability of the findings of this study.
Conclusions
This study demonstrated that serum MMP-2 and MMP-
9 concentrations in the study subjects were significantly
higher in arsenic-endemic areas than in non-endemic
area. Increased serum MMP-2 and MMP-9 concentra-
tions showed significant associations with the increasing
concentrations of drinking water, hair and nail arsenic
of the study subjects. Arsenic exposure exhibited
dose–response relationships with serum MMP-2 and
MMP-9 concentrations. Furthermore, both MMPs were
positively correlated with each other. Finally, serum
MMP-2 and MMP-9 concentrations showed associations
with the several circulating markers of CVDs. Thus, the
results of this study suggest that arsenic exposure-related
elevation of serum MMP-2 and MMP-9 concentrations
may be implicated in arsenic-induced CVDs.
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